OncologyASCO 2026

Talazoparib (Talzenna) — TALAPRO-3

Pfizer

PARP inhibitor in metastatic castration-sensitive prostate cancer without HRR biomarker selection. TALAPRO-3 toplined positive March 2026. ASCO 2026 late-breaker LBA5007.

Prostate CancermCSPC

Linked Studies

NCT04821622PrimaryACTIVE_NOT_RECRUITINGPHASE3

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate CancerUpdated Apr 2026

Loading comments…

Also Known As

Other names

talazoparib

Search all trials →Request coverage update